198 related articles for article (PubMed ID: 27385099)
1. The anti-cancer activity of the mTORC1/2 dual inhibitor XL388 in preclinical osteosarcoma models.
Zhu YR; Zhou XZ; Zhu LQ; Yao C; Fang JF; Zhou F; Deng XW; Zhang YQ
Oncotarget; 2016 Aug; 7(31):49527-49538. PubMed ID: 27385099
[TBL] [Abstract][Full Text] [Related]
2. The anti-osteosarcoma cell activity by a mTORC1/2 dual inhibitor RES-529.
Hu X; Wang Z; Chen M; Chen X; Liang W
Biochem Biophys Res Commun; 2018 Mar; 497(2):499-505. PubMed ID: 29432734
[TBL] [Abstract][Full Text] [Related]
3. Dual mTORC1/2 inhibition by INK-128 results in antitumor activity in preclinical models of osteosarcoma.
Jiang H; Zeng Z
Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):255-61. PubMed ID: 26514724
[TBL] [Abstract][Full Text] [Related]
4. The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent.
Xiong Z; Zang Y; Zhong S; Zou L; Wu Y; Liu S; Fang Z; Shen Z; Ding Q; Chen S
Oncotarget; 2017 May; 8(18):30151-30161. PubMed ID: 28404914
[TBL] [Abstract][Full Text] [Related]
5. The mTOR Kinase Inhibitor CZ415 Inhibits Human Papillary Thyroid Carcinoma Cell Growth.
Li X; Li Z; Song Y; Liu W; Liu Z
Cell Physiol Biochem; 2018; 46(2):579-590. PubMed ID: 29617677
[TBL] [Abstract][Full Text] [Related]
6. Autophagy inhibition sensitizes WYE-354-induced anti-colon cancer activity in vitro and in vivo.
Wang L; Zhu YR; Wang S; Zhao S
Tumour Biol; 2016 Sep; 37(9):11743-11752. PubMed ID: 27020593
[TBL] [Abstract][Full Text] [Related]
7. The therapeutic value of XL388 in human glioma cells.
Zhong S; Xue J; Cao JJ; Sun B; Sun QF; Bian LG; Hu LY; Pan SJ
Aging (Albany NY); 2020 Nov; 12(22):22550-22563. PubMed ID: 33159013
[TBL] [Abstract][Full Text] [Related]
8. Identification of DNA-PKcs as a primary resistance factor of salinomycin in osteosarcoma cells.
Zhen YF; Li ST; Zhu YR; Wang XD; Zhou XZ; Zhu LQ
Oncotarget; 2016 Nov; 7(48):79417-79427. PubMed ID: 27765904
[TBL] [Abstract][Full Text] [Related]
9. Targeting mTOR by CZ415 Inhibits Head and Neck Squamous Cell Carcinoma Cells.
Xie J; Li Q; Ding X; Gao Y
Cell Physiol Biochem; 2018; 46(2):676-686. PubMed ID: 29621758
[TBL] [Abstract][Full Text] [Related]
10. mTOR signaling intervention by Torin1 and XL388 in the insular cortex alleviates neuropathic pain.
Choi S; Kim K; Cha M; Kim M; Lee BH
Neurosci Lett; 2020 Jan; 718():134742. PubMed ID: 31917234
[TBL] [Abstract][Full Text] [Related]
11. Targeting the mTOR pathway using novel ATP‑competitive inhibitors, Torin1, Torin2 and XL388, in the treatment of glioblastoma.
Amin AG; Jeong SW; Gillick JL; Sursal T; Murali R; Gandhi CD; Jhanwar-Uniyal M
Int J Oncol; 2021 Oct; 59(4):. PubMed ID: 34523696
[TBL] [Abstract][Full Text] [Related]
12. Crosstalk between the IGF-1R/AKT/mTORC1 pathway and the tumor suppressors p53 and p27 determines cisplatin sensitivity and limits the effectiveness of an IGF-1R pathway inhibitor.
Davaadelger B; Duan L; Perez RE; Gitelis S; Maki CG
Oncotarget; 2016 May; 7(19):27511-26. PubMed ID: 27050276
[TBL] [Abstract][Full Text] [Related]
13. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
[TBL] [Abstract][Full Text] [Related]
14. Cytoprotective role of autophagy during paclitaxel-induced apoptosis in Saos-2 osteosarcoma cells.
Kim HJ; Lee SG; Kim YJ; Park JE; Lee KY; Yoo YH; Kim JM
Int J Oncol; 2013 Jun; 42(6):1985-92. PubMed ID: 23563171
[TBL] [Abstract][Full Text] [Related]
15. The Antipancreatic Cancer Activity of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2.
Chen B; Xu M; Zhang H; Xu MZ; Wang XJ; Tang QH; Tang JY
DNA Cell Biol; 2015 Oct; 34(10):610-7. PubMed ID: 26284306
[TBL] [Abstract][Full Text] [Related]
16. Liposomal short-chain C6 ceramide induces potent anti-osteosarcoma activity in vitro and in vivo.
Zhai L; Sun N; Han Z; Jin HC; Zhang B
Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):274-80. PubMed ID: 26505795
[TBL] [Abstract][Full Text] [Related]
17. C6 ceramide sensitizes the anti-hepatocellular carcinoma (HCC) activity by AZD-8055, a novel mTORC1/2 dual inhibitor.
Liu M; Gu P; Guo W; Fan X
Tumour Biol; 2016 Aug; 37(8):11039-48. PubMed ID: 26897748
[TBL] [Abstract][Full Text] [Related]
18. Bromodomain-Containing Protein 4 (BRD4) Inhibition Sensitizes Palomid 529-Induced Anti-Renal Cell Carcinoma Cell Activity in Vitro and in Vivo.
Xing ZY; Wang Y; Cheng L; Chen J; He XZ; Xing W
Cell Physiol Biochem; 2018; 50(2):640-653. PubMed ID: 30308518
[TBL] [Abstract][Full Text] [Related]
19. mTOR: An attractive therapeutic target for osteosarcoma?
Ding L; Congwei L; Bei Q; Tao Y; Ruiguo W; Heze Y; Bo D; Zhihong L
Oncotarget; 2016 Aug; 7(31):50805-50813. PubMed ID: 27177330
[TBL] [Abstract][Full Text] [Related]
20. Cardiomyocyte apoptosis vs autophagy with prolonged doxorubicin treatment: comparison with osteosarcoma cells.
Tacar O; Indumathy S; Tan ML; Baindur-Hudson S; Friedhuber AM; Dass CR
J Pharm Pharmacol; 2015 Feb; 67(2):231-43. PubMed ID: 25208656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
